Article    Table of Contents                    Full Text of this article Free    Figures/Tables List  Services    Send comment/rapid response letter    Notify a friend about this article    Alert me when this article is cited    Add to Personal Archive    Download to Citation Manager    ACP Search                            Get Permissions  Google Scholar    Search for Related Content  PubMed Articles in PubMed by Author:    Gibril, F.    Jensen, R. T.    Related Articles in PubMed    PubMed Citation    PubMed

ARTICLE

Somatostatin Receptor Scintigraphy: Its Sensitivity Compared with That of Other Imaging Methods in Detecting Primary and Metastatic Gastrinomas: A Prospective Study

Fathia Gibril, MD; James C. Reynolds, MD; John L. Doppman, MD; Clara C. Chen, MD; David J. Venzon, PhD; Basel Termanini, MD; H. Christian Weber, MD; Charmaine A. Stewart, MD; and Robert T. Jensen, MD

1 July 1996 | Volume 125 Issue 1 | Pages 26-34

Objective: To compare the sensitivity of somatostatin receptor scintigraphy done using [¹¹¹In-DTPA-DPhe¹]octreotide with that of other imaging methods in the localization of gastrinomas in patients with the Zollinger-Ellison syndrome.

Design: Prospective study.

Setting: Referral-based clinical research center.

Patients: 80 consecutive patients with the Zollinger-Ellison syndrome.

Interventions: Conventional tumor localization studies (ultrasonography, computed tomography [CT], magnetic resonance imaging [MRI], selective angiography, and bone scanning) and somatostatin receptor scintigraphy done using [¹¹¹In-DTPA-DPhe¹]octreotide with single-photon emission CT imaging at 4 and 24 hours. Patients with possible liver metastases had biopsies done for confirmation, and 15 patients had exploratory laparotomies done to assess primary tumor localization.

Results: Extrahepatic gastrinomas or liver metastases were identified by ultrasonography in 19% of patients, by CT in 38% of patients, by MRI in 45% of patients, by angiography in 40% of patients, and by somatostatin receptor scintigraphy in 70% of patients. Somatostatin receptor scintigraphy was as sensitive as the other tests combined (59%), and when the results of all other tests were added to the somatostatin receptor scintigraphy results, tumors were localized in 75% of patients. Among patients with a possible primary tumor, the results of ultrasonography were positive in 9%, the results of CT were positive in 31%, the results of MRI were positive in 30%, the results of angiography were positive in 28%, and the results of somatostatin receptor scintigraphy were positive in 58%. Somatostatin receptor scintigraphy was as sensitive as all of the other imaging studies combined; when the results of scintigraphy were added to the results of the other studies, possible primary tumors were identified in 68% of patients. In 24 patients who had histologically proven metastatic liver disease, sensitivities for the detection of any metastatic liver lesions were 46% for ultrasonography, 42% for CT, 71% for MRI, 62% for angiography, and 92% for somatostatin receptor scintigraphy. Somatostatin receptor scintigraphy was significantly better than all of the conventional imaging methods in the identification of gastrinomas later found at surgery (P = 0.004), but it still missed 20% of gastrinomas.

Conclusions: Somatostatin receptor scintigraphy is the single most sensitive method for imaging either primary or metastatic liver lesions in patients with the Zollinger-Ellison syndrome. Because of its sensitivity, simplicity, and cost-effectiveness, it should be the first imaging method used in these patients. For patients with negative results on somatostatin receptor scintigraphy, guidelines about the use of other imaging studies are proposed.

Author and Article Information

From the National Institutes of Health, Bethesda, Maryland.
Requests for Reprints: Robert T. Jensen, National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases/Digestive Diseases Branch, Building 10, Room 9C-103, 10 Center Drive, MSC 1804, Bethesda, MD 20892-1804.
Current Author Addresses: Drs. Gibril, Termanini, Weber, Stewart, and Jensen: National Institute of Health/National Institute of Diabetes and Digestive and Kidney Diseases/Digestive Diseases Branch, Building 10, Room 9C-103, 10 Center Drive, MSC 1804, Bethesda, MD 20892-1804.

This article has been cited by other articles:

				M. Korner, B. Waser, and J. C. Reubi High Expression of Neuropeptide Y1 Receptors in Ewing Sarcoma Tumors Clin. Cancer Res., August 15, 2008; 14(16): 5043 - 5049. [Abstract] [Full Text] [PDF]

				S. Leboulleux, C. Dromain, A. L. Vataire, D. Malka, A. Auperin, J. Lumbroso, P. Duvillard, D. Elias, D. M. Hartl, T. De Baere, et al. Prediction and Diagnosis of Bone Metastases in Well-Differentiated Gastro-Entero-Pancreatic Endocrine Cancer: A Prospective Comparison of Whole Body Magnetic Resonance Imaging and Somatostatin Receptor Scintigraphy J. Clin. Endocrinol. Metab., August 1, 2008; 93(8): 3021 - 3028. [Abstract] [Full Text] [PDF]

				D. A. Mankoff, J. M. Link, H. M. Linden, L. Sundararajan, and K. A. Krohn Tumor Receptor Imaging J. Nucl. Med., June 1, 2008; 49(Suppl_2): 149S - 163S. [Abstract] [Full Text] [PDF]

				R. T. Jensen, J. F. Battey, E. R. Spindel, and R. V. Benya International Union of Pharmacology. LXVIII. Mammalian Bombesin Receptors: Nomenclature, Distribution, Pharmacology, Signaling, and Functions in Normal and Disease States Pharmacol. Rev., March 1, 2008; 60(1): 1 - 42. [Abstract] [Full Text] [PDF]

				M. Korner, M. Stockli, B. Waser, and J. C. Reubi GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting J. Nucl. Med., May 1, 2007; 48(5): 736 - 743. [Abstract] [Full Text] [PDF]

				D. Wild, M. Behe, A. Wicki, D. Storch, B. Waser, M. Gotthardt, B. Keil, G. Christofori, J. C. Reubi, and H. R. Macke [Lys40(Ahx-DTPA-111In)NH2]Exendin-4, a Very Promising Ligand for Glucagon-like Peptide-1 (GLP-1) Receptor Targeting J. Nucl. Med., December 1, 2006; 47(12): 2025 - 2033. [Abstract] [Full Text] [PDF]

				M. Korner, G. M. Hayes, R. Rehmann, A. Zimmermann, H. Friess, L. J. Miller, and J. C. Reubi Secretin Receptors in Normal and Diseased Human Pancreas: Marked Reduction of Receptor Binding in Ductal Neoplasia Am. J. Pathol., October 1, 2005; 167(4): 959 - 968. [Abstract] [Full Text] [PDF]

				J K Ramage, A H G Davies, J Ardill, N Bax, M Caplin, A Grossman, R Hawkins, A M McNicol, N Reed, R Sutton, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours Gut, June 1, 2005; 54(suppl_4): iv1 - iv16. [Full Text] [PDF]

				C. Dromain, T. de Baere, J. Lumbroso, H. Caillet, A. Laplanche, V. Boige, M. Ducreux, P. Duvillard, D. Elias, M. Schlumberger, et al. Detection of Liver Metastases From Endocrine Tumors: A Prospective Comparison of Somatostatin Receptor Scintigraphy, Computed Tomography, and Magnetic Resonance Imaging J. Clin. Oncol., January 1, 2005; 23(1): 70 - 78. [Abstract] [Full Text] [PDF]

				M. Korner, B. Waser, and J. C. Reubi High Expression of Neuropeptide Y Receptors in Tumors of the Human Adrenal Gland and Extra-Adrenal Paraganglia Clin. Cancer Res., December 15, 2004; 10(24): 8426 - 8433. [Abstract] [Full Text] [PDF]

				B. Asgharian, M. L. Turner, F. Gibril, L. K. Entsuah, J. Serrano, and R. T. Jensen Cutaneous Tumors in Patients with Multiple Endocrine Neoplasm Type 1 (MEN1) and Gastrinomas: Prospective Study of Frequency and Development of Criteria with High Sensitivity and Specificity for MEN1 J. Clin. Endocrinol. Metab., November 1, 2004; 89(11): 5328 - 5336. [Abstract] [Full Text] [PDF]

				B. Van Den Bossche and C. Van de Wiele Receptor Imaging in Oncology by Means of Nuclear Medicine: Current Status J. Clin. Oncol., September 1, 2004; 22(17): 3593 - 3607. [Abstract] [Full Text] [PDF]

				G. A. Kaltsas, G. M. Besser, and A. B. Grossman The Diagnosis and Medical Management of Advanced Neuroendocrine Tumors Endocr. Rev., June 1, 2004; 25(3): 458 - 511. [Abstract] [Full Text] [PDF]

				E. J. Rolleman, E. P. Krenning, A. van Gameren, B. F. Bernard, and M. de Jong Uptake of [111In-DTPA0]Octreotide in the Rat Kidney Is Inhibited by Colchicine and Not by Fructose J. Nucl. Med., April 1, 2004; 45(4): 709 - 713. [Abstract] [Full Text] [PDF]

				B. Asgharian, Y.-J. Chen, N. J. Patronas, P. L. Peghini, J. C. Reynolds, A. Vortmeyer, Z. Zhuang, D. J. Venzon, F. Gibril, and R. T. Jensen Meningiomas May Be a Component Tumor of Multiple Endocrine Neoplasia Type 1 Clin. Cancer Res., February 1, 2004; 10(3): 869 - 880. [Abstract] [Full Text] [PDF]

				J. Bertherat, F. Tenenbaum, K. Perlemoine, C. Videau, J. L. Alberini, B. Richard, B. Dousset, X. Bertagna, and J. Epelbaum Somatostatin Receptors 2 and 5 Are the Major Somatostatin Receptors in Insulinomas: An in Vivo and in Vitro Study J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5353 - 5360. [Abstract] [Full Text] [PDF]

				J. C. Reubi Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy Endocr. Rev., August 1, 2003; 24(4): 389 - 427. [Abstract] [Full Text] [PDF]

				F. Panzuto, M. Falconi, S. Nasoni, S. Angeletti, A. Moretti, M. Bezzi, G. Gualdi, E. Polettini, R. Sciuto, A. Festa, et al. Staging of digestive endocrine tumours using helical computed tomography and somatostatin receptor scintigraphy Ann. Onc., April 1, 2003; 14(4): 586 - 591. [Abstract] [Full Text] [PDF]

				F. Gibril, Y.-J. Chen, D. S. Schrump, A. Vortmeyer, Z. Zhuang, I. A. Lubensky, J. C. Reynolds, A. Louie, L. K. Entsuah, K. Huang, et al. Prospective Study of Thymic Carcinoids in Patients with Multiple Endocrine Neoplasia Type 1 J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 1066 - 1081. [Abstract] [Full Text] [PDF]

				O. Schillaci, A. Spanu, F. Scopinaro, A. Falchi, R. Danieli, P. Marongiu, N. Pisu, G. Madeddu, G. Delle Fave, and G. Madeddu Somatostatin Receptor Scintigraphy in Liver Metastasis Detection from Gastroenteropancreatic Neuroendocrine Tumors J. Nucl. Med., March 1, 2003; 44(3): 359 - 368. [Abstract] [Full Text] [PDF]

				Y.-J. Chen, A. Vortmeyer, Z. Zhuang, S. Huang, and R. T. Jensen Loss of Heterozygosity of Chromosome 1q in Gastrinomas: Occurrence and Prognostic Significance Cancer Res., February 15, 2003; 63(4): 817 - 823. [Abstract] [Full Text] [PDF]

				P. L. Peghini, M. Iwamoto, M. Raffeld, Y.-J. Chen, S. U. Goebel, J. Serrano, and R. T. Jensen Overexpression of Epidermal Growth Factor and Hepatocyte Growth Factor Receptors in a Proportion of Gastrinomas Correlates with Aggressive Growth and Lower Curability Clin. Cancer Res., July 1, 2002; 8(7): 2273 - 2285. [Abstract] [Full Text] [PDF]

				N Power and R H Reznek Imaging pancreatic islet cell tumours Imaging, April 1, 2002; 14(2): 147 - 159. [Abstract] [Full Text] [PDF]

				F. Gibril, D. J. Venzon, J. V. Ojeaburu, S. Bashir, and R. T. Jensen Prospective Study of the Natural History of Gastrinoma in Patients with MEN1: Definition of an Aggressive and a Nonaggressive Form J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5282 - 5293. [Abstract] [Full Text] [PDF]

				E. Even-Sapir, Z. Keidar, J. Sachs, A. Engel, L. Bettman, D. Gaitini, L. Guralnik, N. Werbin, G. Iosilevsky, and O. Israel The New Technology of Combined Transmission and Emission Tomography in Evaluation of Endocrine Neoplasms J. Nucl. Med., July 1, 2001; 42(7): 998 - 1004. [Abstract] [Full Text] [PDF]

				A. C. Berger, F. Gibril, D. J. Venzon, J. L. Doppman, J. A. Norton, D. L. Bartlett, S. K. Libutti, R. T. Jensen, and H. R. Alexander Prognostic Value of Initial Fasting Serum Gastrin Levels in Patients With Zollinger-Ellison Syndrome J. Clin. Oncol., June 15, 2001; 19(12): 3051 - 3057. [Abstract] [Full Text] [PDF]

				C. Bordi, V. D. Corleto, C. Azzoni, S. Pizzi, G. Ferraro, F. Gibril, G. Delle Fave, and R. T. Jensen The Antral Mucosa as a New Site for Endocrine Tumors in Multiple Endocrine Neoplasia Type 1 and Zollinger-Ellison Syndromes J. Clin. Endocrinol. Metab., May 1, 2001; 86(5): 2236 - 2242. [Abstract] [Full Text]

				J. Serrano, S. U. Goebel, P. L. Peghini, I. A. Lubensky, F. Gibril, and R. T. Jensen Alterations in the p16INK4a/CDKN2A Tumor Suppressor Gene in Gastrinomas J. Clin. Endocrinol. Metab., November 1, 2000; 85(11): 4146 - 4156. [Abstract] [Full Text]

				R. T. Jensen Somatostatin Receptor-Based Scintigraphy and Antitumor Treatment--An Expanding Vista? J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3507 - 3508. [Full Text]

				F. Gibril, J. C. Reynolds, I. A. Lubensky, P. K. Roy, P. L. Peghini, J. L. Doppman, and R. T. Jensen Ability of Somatostatin Receptor Scintigraphy to Identify Patients with Gastric Carcinoids: A Prospective Study J. Nucl. Med., October 1, 2000; 41(10): 1646 - 1656. [Abstract] [Full Text] [PDF]

				S. Froidevaux, A. Heppeler, A. N. Eberle, A.-M. Meier, M. Hausler, C. Beglinger, M. Behe, P. Powell, and H. R. Macke Preclinical Comparison in AR4-2J Tumor-Bearing Mice of Four Radiolabeled 1,4,7,10-Tetraazacyclododecane-1,4,7,10-Tetraacetic Acid-Somatostatin Analogs for Tumor Diagnosis and Internal Radiotherapy Endocrinology, September 1, 2000; 141(9): 3304 - 3312. [Abstract] [Full Text] [PDF]

				S. U. Goebel, C. Heppner, A. L. Burns, S. J. Marx, A. M. Spiegel, Z. Zhuang, I. A. Lubensky, F. Gibril, R. T. Jensen, and J. Serrano Genotype/Phenotype Correlation of Multiple Endocrine Neoplasia Type 1 Gene Mutations in Sporadic Gastrinomas J. Clin. Endocrinol. Metab., January 1, 2000; 85(1): 116 - 123. [Abstract] [Full Text]

				J. A. Norton, D. L. Fraker, H. R. Alexander, D. J. Venzon, J. L. Doppman, J. Serrano, S. U. Goebel, P. L. Peghini, P. K. Roy, F. Gibril, et al. Surgery to Cure the Zollinger-Ellison Syndrome N. Engl. J. Med., August 26, 1999; 341(9): 635 - 644. [Abstract] [Full Text] [PDF]

				S. Froidevaux, E. Hintermann, M. Torok, H. R. Macke, C. Beglinger, and A. N. Eberle Differential Regulation of Somatostatin Receptor Type 2 (sst 2) Expression in AR4-2J Tumor Cells Implanted into Mice during Octreotide Treatment Cancer Res., August 1, 1999; 59(15): 3652 - 3657. [Abstract] [Full Text] [PDF]

				F. Yu, D. J. Venzon, J. Serrano, S. U. Goebel, J. L. Doppman, F. Gibril, and R. T. Jensen Prospective Study of the Clinical Course, Prognostic Factors, Causes of Death, and Survival in Patients With Long-Standing Zollinger-Ellison Syndrome J. Clin. Oncol., February 1, 1999; 17(2): 615 - 615. [Abstract] [Full Text] [PDF]

				J C Reubi, B Waser, H Friess, M Buchler, and J Laissue Neurotensin receptors: a new marker for human ductal pancreatic adenocarcinoma Gut, April 1, 1998; 42(4): 546 - 550. [Abstract] [Full Text] [PDF]